Simcere Zaiming, Inc. - 20 Jun 2025 Form 3/A - Amendment Insider Report for NextCure, Inc. (NXTC)

Reporting relationship: 10%+ Owner
Issuer ticker: NXTC
Reported as of: 20 Jun 2025
Net transaction value: $0
SEC form: 3/A - Amendment
Accepted by SEC: 29 Sep 2025, 16:00:11 UTC
Original report date: 19 Aug 2025
Source filing: View source filing
Reporting owner signature: Simcere Zaiming, Inc. By: /s/ Renhong Tang, Chief Executive Officer

Key filing fact

Simcere Zaiming, Inc. filed Form 3/A - Amendment for NextCure, Inc. (NXTC) on 29 Sep 2025.

Key facts

This page summarizes Simcere Zaiming, Inc.'s Form 3/A - Amendment filing for NextCure, Inc. (NXTC).
0 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 29 Sep 2025, 16:00.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3/A - Amendment disclosures.

View source filing

Reporting Owners (6)

CIK 0002080252 Primary reporting owner

Simcere Zaiming, Inc.

Relationship: 10%+ Owner
Address: 20 ACORN PARK DR., CAMBRIDGE
Signature: Simcere Zaiming, Inc. By: /s/ Renhong Tang, Chief Executive Officer
Signature date: 29 Sep 2025

CIK 0002082506

Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.

Relationship: 10%+ Owner
Address: BUILDING 23, NO.699-18,, XUANWU AVENUE, NANJING, NANJING CITY, JIANGSU PROVINCE, CHINA
Signature: Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. By: /s/ Renhong Tang Director and Attorney-in-Fact
Signature date: 29 Sep 2025

CIK 0002088064

Hainan Simcere Zaiming Pharmaceutical Co., Ltd.

Relationship: 10%+ Owner
Address: NO 20, YAOGUYIHENG ROAD,, XIUYING DISTRICT, HAIKOU CITY, HAINAN PROVINCE, CHINA
Signature: Hainan Simcere Zaiming Pharmaceutical Co., Ltd. By: /s/ Renhong Tang Chief Executive Officer and Chairman of the Board of Directors
Signature date: 29 Sep 2025

CIK 0002082516

Simcere Pharmaceutical Group Ltd

Relationship: 10%+ Owner
Address: BUILDING 23, NO.699-18,, XUANWU AVENUE, NANJING CITY, JIANGSU PROVINCE, CHINA
Signature: Simcere Pharmaceutical Group Limited By: /s/ Jinsheng Ren Chief Executive Officer and Chairman of the Board of Directors
Signature date: 29 Sep 2025

CIK 0001455397

Ren Jinsheng

Relationship: 10%+ Owner
Address: BUILDING 23, NO.699-18,, XUANWU AVENUE, NANJING CITY, JIANGSU PROVINCE, CHINA
Signature: Jinsheng Ren By: /s/ Jinsheng Ren
Signature date: 29 Sep 2025

CIK 0002088593

Tang Renhong

Relationship: 10%+ Owner
Address: BUILDING 23, NO.699-18,, XUANWU AVENUE, NANJING CITY, JIANGSU PROVINCE, CHINA
Signature: Renhong Tang By: /s/ Renhong Tang
Signature date: 29 Sep 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NXTC holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 338,636
Date: 20 Jun 2025
Ownership: See footnotes
Footnotes: F1, F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

These securities are directly held by Simcere Zaiming, Inc. ("Simcere Zaiming") and may be deemed to be indirectly beneficially owned by the other reporting persons (the "Reporting Persons").

Footnote F2

Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. ("Jiangsu Zaiming") is the sole shareholder of Simcere Zaiming, Inc. Hainan Simcere Zaiming Pharmaceutical Co., Ltd. ("Hainan Zaiming") is the sole shareholder of Jiangsu Zaiming. Simcere Pharmaceutical Group Limited ("Simcere Group") is the controlling shareholder of Hainan Zaiming through several intermediate companies. Mr. Ren Jinsheng is the chief executive officer and chairman of the board of directors of Simcere Group and a director of Hainan Zaiming. Mr. Tang Renhong is a director of Simcere Group, the chief executive officer and chairman of the board of directors of Hainan Zaiming, a director of Jiangsu Zaiming and the chief executive officer and sole director of Simcere Zaiming. Messrs. Ren Jinsheng and Tang Renhong may be deemed to be the beneficial owners having shared voting power and shared investment power over the securities described in this footnote.

Footnote F3

The Reporting Persons disclaim beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that any Reporting Person is the beneficial owner of any of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Footnote F4

This amendment is being made solely for the purpose of including Jiangsu Zaiming, Hainan Zaiming, Simcere Group, Mr. Ren Jinsheng and Mr. Tang Renhong as additional reporting persons to the Form 3 filed by Simcere Zaiming on 8/19/2025 (the "Original Form"). Although Jiangsu Zaiming, Hainan Zaiming, Simcere Group, Mr. Ren Jinsheng and Mr. Tang Renhong were disclosed in the Original Form, they were unable to be included as reporting persons because they did not have codes for, or lost electronic access to, the EDGAR system at the time. Other than including Jiangsu Zaiming, Hainan Zaiming, Simcere Group, Mr. Ren Jinsheng and Mr. Tang Renhong as additional reporting persons, this form contains no amendment to the Original Form.

SEC remarks

Exhibit List: Exhibit 24 - Power of Attorney, incorporated by reference to Exhibit 24 to the Schedule 13G filed by Reporting Persons with the Securities and Exchange Commission on August 19, 2025